METASTATIC MELANOMA

This study tested a new type of vaccine made by fusing a patient's own immune cells with their cancer cells. The goal was to see if it could safely train the immune system to attack advanced melanoma. Twenty adults with worsening metastatic melanoma received the vaccine. Research…

This study tested a drug called Taxoprexin in 22 people with advanced eye melanoma that had spread to other parts of the body. The goal was to see if the drug could shrink tumors and how safe it was. Participants received weekly injections, and researchers measured tumor response…

This study tested a powerful mix of a targeted drug (vemurafenib), specially grown immune cells (T-cells), and high-dose IL-2 in 17 people with advanced melanoma that had spread. The goal was to see if this combination could shrink tumors and keep patients alive longer. The appro…

This study tested a weekly chemotherapy drug called Taxoprexin in 30 people with advanced melanoma that had spread to other parts of the body. The goal was to see if the drug could shrink tumors and how long that effect might last. Participants had not received chemotherapy befor…

This study tested a new treatment for people with advanced melanoma that has spread or cannot be removed. The treatment uses a patient's own immune cells, called tumor-infiltrating lymphocytes (TILs), which are grown in a lab and then given back to the patient. The goal was to se…

This early-stage trial tested the safety of a new drug called IN10018, given alone or with other medicines, in 51 adults with advanced melanoma that had spread. The goal was to see if the treatment was safe and tolerable, not to cure the disease. Participants had either uveal mel…

This study tested a combination of two immunotherapy drugs, low-dose ipilimumab and pembrolizumab, in 24 people with advanced melanoma that had spread to the brain. The goal was to see if the treatment could shrink or control brain tumors. Participants received the drugs intraven…

This early-phase study tested a new treatment called TBio-4101 for people with advanced melanoma that did not respond to standard therapies. The treatment uses a patient's own immune cells (TILs) that are grown in a lab and given back after chemotherapy and a drug called IL-2. Th…

This study tested whether adding total body radiation to standard chemotherapy before a cell therapy infusion helps people with advanced melanoma. Participants had their own immune cells taken from a tumor, grown in a lab, and then returned to them. The goal was to see if the ext…

This study tested a lower dose of chemotherapy given before infusing a patient's own tumor-fighting immune cells (lifileucel) for melanoma that has spread or can't be removed. Eleven adults with advanced melanoma took part. The goal was to see if the milder chemo prep still allow…

This small early-phase study tested whether combining a topical skin cream (imiquimod) with an immunotherapy drug (pembrolizumab) is safe and effective for people with advanced melanoma that has spread. Seven participants with stage IIIB-IV melanoma were enrolled. The goal was to…

This study tested a treatment for advanced melanoma that uses a patient's own immune cells (called TIL) grown in a lab and given back with high-dose IL-2. The goal was to see if this approach was possible and safe. 19 people with stage IV or stage III melanoma took part. The trea…

This pilot study tested a new treatment for advanced melanoma that has spread. It combined immune cells grown from the patient's own tumor (TILs) with an immunotherapy drug called ipilimumab. The goal was to see if this combination was safe and possible to give. 13 people took pa…

This early-stage study tested a combination of an immunotherapy drug (pembrolizumab) and precise radiation (stereotactic radiosurgery) in 25 people with melanoma or lung cancer that had spread to the brain. The main goal was to check for serious side effects. The approach aims to…

This study tested whether combining oral azacitidine with pembrolizumab can help control advanced melanoma that has spread. It involved 24 adults with stage III or IV melanoma who either had not received prior PD-1 therapy or had progressed on it. The goal was to see how many pat…

This study looked at whether a blood sample can find genetic changes in advanced melanoma, instead of taking a piece of the tumor with a needle or surgery. Researchers tested blood from 50 people with metastatic melanoma to see if they could spot key mutations. The goal is to mak…

This study tested a special counseling program called CALM (Managing Cancer and Living Meaningfully) for people with brain cancer. 60 participants were split into two groups: one received CALM plus usual care, the other just usual care. The goal was to see if CALM is practical an…

This study observed about 400 adults with advanced BRAF-mutant melanoma who were taking targeted therapy (BRAF/MEK inhibitors) and using a smartphone app called TavieSkin. The goal was to describe patient characteristics, how they used the app, and their quality of life. No new t…

This study looked at 32 people with advanced melanoma who were treated with the immunotherapy drug Nivolumab (Anti-PD1). The goal was to understand how the immune system changes during treatment and why some patients respond well while others do not. By analyzing blood samples be…

This study compared two blood test methods (EPISPOT and CellSearch) for finding circulating melanoma cells in people with advanced melanoma. Researchers took blood samples from 73 participants, including patients with stage 4 melanoma and hospitalized controls without cancer. The…

This study looked at whether people with advanced cancers (melanoma, kidney, or lung cancer) receiving first-line immunotherapy can successfully collect small blood samples at home using a finger-prick method. 24 patients participated, and the goal was to see if home testing is p…

This study enrolled 5 people with advanced melanoma who were starting treatment with nivolumab (with or without ipilimumab). Researchers took blood and skin samples to track how immune cells changed during therapy, aiming to spot differences between those who responded to treatme…

This study looked at 132 people with advanced melanoma to see if levels of a protein called interferon-gamma (IFN-γ) in tumor tissue and blood could predict how well they would respond to first-line immunotherapy drugs. Researchers also explored whether gut bacteria play a role i…

This early study tested whether giving a single dose of immune-boosting drugs (nivolumab with either ipilimumab or relatlimab) before brain surgery is safe and possible for people with melanoma that has spread to the brain. Only one person took part, so the main goal was to see i…